Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL.

Northend, Michael, Wilson, William, Osborne, Wendy, Fox, Christopher P, Davies, Andrew J, El-Sharkawi, Dima, Phillips, Elizabeth H, Sim, Hau Wui, Sadullah, Shalal, Shah, Nimish, Peng, Ying Ying, Qureshi, Iman, Addada, Juanah, Mora, Rocio Figueroa, Phillips, Neil, Kuhnl, Andrea, Davies, Elizabeth, Wrench, David, McKay, Pamela, Karpha, Indrani, Cowley, Anna, Karim, Richard, Challenor, Sarah, Singh, Vikram, Burton, Cathy, Auer, Rebecca, Williams, Chris, Cunningham, Joel, Broom, Angus, Arasaretnam, Anita, Roddie, Claire, Menne, Tobias and Townsend, William (2022) Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL. Blood advances, 6 (9). pp. 2920-2926. ISSN 2473-9537. This article is available to all UHB staff and students login using a UHB Athens Account. Register for Athens here - https://openathens.nice.org.uk/

Full text not available from this repository.
Official URL: https://ashpublications.org/bloodadvances/article/...
Item Type: Article
Additional Information: This article is available to all UHB staff and students login using a UHB Athens Account. Register for Athens here - https://openathens.nice.org.uk/
Subjects: QZ Pathology. Oncology
Related URLs:
Depositing User: Sarah Gee
Date Deposited: 28 Jun 2022 08:10
Last Modified: 28 Jun 2022 08:10
URI: http://www.repository.uhblibrary.co.uk/id/eprint/5661

Actions (login required)

View Item View Item